1.INTRODUCTION
Complex regional pain syndrome (CRPS) is a common and disabling persistent pain condition results from an abnormal tissue response to injury, and increased sensitization of the central and peripheral nervous systems with various symptoms including swelling, limited joint range of motion, autonomic dysregulation and trophic changes in the affected limb. Several cases of CRPS have been reported after vaccination [1,2].
After the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) pandemic, several new and effective vaccines were approved in a relatively short period. However, the safety profile has been subject of concern.
This report describes a young man patient who developed complex regional pain syndrome (CRPS) of the right knee after receiving the second dose of messenger RNA— BNT162b2 (Pfizer–BioNTech) COVID-19 vaccine.